Slide 1: FY 2025 Results
XY Oiasorin FY 2025 RESULTS March 20, 2026
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Business Highlights
BUSINESS HIGHLIGHTS +) Diasorin
Slide 5: Product launches and agreements timeline
Mar Apr Jun Jul Sept Oct Nov Dec Jan Feb Mar 2025 2025 2025 2025 2025 2025 2025 2025 2026 2026 2026 LIAISON LIAISON LIAISON TSH-R QuantiFERON- Delta Hepatitis QuantiFERON- Ab TB Gold Plus II US Market TB Gold Plus II CE Market CE Market US Market Blood culture Simplexa Blood culture Authorization Au
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS +) Diasorin
Slide 7: Q4'25 & FY'25 Revenue Variances
Q4’25 & FY’25 Revenue Variances Q4’25 Group revenues FY’25 Group revenues (figures in €/million - percentage variances @CER’24) (figures in €/million - percentage variances @CER’24) Avg. 2024 EUR/USD FX: 1.08 Avg. 2025 EUR/USD FX: 1.13 Note: YoY variations are presented using 2024 constant exchange
Slide 8: Q4'25 & FY'25 Immunodiagnostic Revenue Variances
Q4’25 & FY’25 Immunodiagnostic Revenue Variances Q4’25 Group revenues FY’25 Group revenues (figures in €/million - percentage variances @CER’24) (figures in €/million - percentage variances @CER’24) Avg. 2024 EUR/USD FX: 1.08 Avg. 2025 EUR/USD FX: 1.13 Base Business (excluding outbreaks and China):
Slide 9: Q4'25 & FY'25 Molecular Diagnostic Revenue Variances
Q4’25 & FY’25 Molecular Diagnostic Revenue Variances Q4’25 Group revenues FY’25 Group revenues (figures in €/million - percentage variances @CER’24) (figures in €/million - percentage variances @CER’24) Avg. 2024 EUR/USD FX: 1.08 Lowplex Multiplex Lowplex Multiplex Avg. 2025 EUR/USD FX: 1.13 Automat
Slide 10: Automated Multiplexing: LIAISON PLEX
Automated Multiplexing: LIAISON PLEX LIAISON PLEX CUSTOMERS: ca. 150 (60% flex vs. 40% fixed) BY NUMBER OF CUSTOMERS BY REVENUE CONTRIBUTION • 10% commercial labs • 55% commercial labs • 90% hospital labs • 45% hospital labs LIAISON PLEX COMMERCIAL LAUNCH UPDATE: • Commercial team fully established
Slide 11: Q4'25 & FY'25 LTG Revenue Variances
Q4’25 & FY’25 LTG Revenue Variances Q4’25 Group revenues FY’25 Group revenues (figures in €/million - percentage variances @CER’24) (figures in €/million - percentage variances @CER’24) Avg. 2024 EUR/USD FX: 1.08 Avg. 2025 EUR/USD FX: 1.13 Life Science clients: • Performance impacted by unfavorable
Slide 12: Q4 & FY 2025 Profitability Profile
Q4 & FY 2025 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ CER. 33% 31% 309 295 In Q4 2025, Adjusted1 EBITDA2 Margin was equal to 31% @ CER, 102 92 mainly due to tariff impacts, an unfavorable technology/geography Net sales mix, and VBP in Chi
Slide 13: FY 2026 Company Guidance and 2026 Outlook
FY 2026 COMPANY GUIDANCE AND 2026 OUTLOOK +) Diasorin
Slide 14: FY'26 Guidance
FY’26 Guidance FY’26 GUIDANCE (@CER 2025) Avg. 2025 EUR/USD FX: 1.13 Avg. Expected 2026 EUR/USD FX: 1.18 (Source: Bloomberg) as of March 19, 2026 1 cent of difference between EUR and USD over 12 months has an impact on: • FY Revenue of ca. €/mln 6-7 • FY EBITDA of ca. €/mln 2-3 1 With reference to t
Slide 15: FY 2026 Top Line Guidance @CER2025
FY 2026 Top Line Guidance @CER2025 Revenue Guidance FY26 • LTG: diagnostic customers are expected to grow at an LSD-to-MSD% 1,195 €/mln Between +5% and +6% rate, offsetting the continued weakness in the Life Science business. +LSD% LTG • Molecular diagnostics: growth driven by the launch of the full
Slide 16: FY26 Growth Trajectory by Quarter
FY26 Growth Trajectory by Quarter 1Q26 2Q26 3Q26 4Q26 • Immunodiagnostics: steady growth across different quarters in FY2026 as a result of the unique specialty menu and the hospital strategy, partially compensated by the normalization of volumes in Europe, with the exception of some tough compariso
Slide 17: Financial Schemes
FINANCIAL SCHEMES +) Diasorin
Slide 18: Income Statement
Income Statement FY Change Amounts in millions of euros 2024 2025 amount % Net Revenues 1,185 1,195 +10 +1% Cost of sales (404) (422) -18 +4% Gross profit 782 773 -8 -1% 66% 65% -122 bps Total operating costs (523) (545) -22 +4% non recurring amount (7) (41) -34 n.m EBIT 258 229 -30 -12% 22% 19% -26
Slide 19: Balance Sheet
Balance Sheet Amounts in millions of euros 12/31/2024 12/31/2025 Change Goodwill and intangibles assets 2,028 1,790 -239 Property, plant and equipment 271 256 -16 Other non-current assets 34 42 +8 Net working capital 346 325 -21 Other non-current liabilities (264) (257) +7 Net Invested Capital 2,417
Slide 20: Cash Flow Statement
Cash Flow Statement FY Amounts in millions of euros 2024 2025 Cash and cash equivalents at the beginning of the period 280 344 Cash provided by operating activities 359 343 Cash provided/(used) in investing activities (50) (144) Cash provided/(used) in financing activities (245) (377) Net change in
Slide 21: FY'25 Reconciliation to Consolidated Financial Statements
FY’25 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 773 375 229 150 % on Revenues 65% 31% 19% 13% Adjustments “One-off” costs related to non recurring events 4 19 39 39 Depreciation of Luminex intang
Slide 22: FY'24 Reconciliation to Consolidated Financial Statements
FY’24 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 782 387 258 187 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 6 6 6 Depreciat
Slide 23: Slide 23